Nascent Biotech, Inc. (NBIO)

Nascent Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	-	-	-	1	0.75	-
Revenue Growth (YoY)	-	-	-	33.33%	-	-
Cost of Revenue	0.32	0.32	-	-	-	-
Gross Profit	-0.32	-0.32	-	1	0.75	-
Selling, General & Admin	1.71	1.71	1.5	0.93	1.83	3.15
Research & Development	0.2	0.2	0.65	0.53	0.32	0.29
Operating Expenses	1.91	1.91	2.16	1.46	2.15	3.45
Operating Income	-2.23	-2.23	-2.16	-0.46	-1.4	-3.45
Interest Expense	-0.39	-0.39	-1.72	-0.34	-0.34	-0.09
Interest & Investment Income	0.01	0.01	0	0	0	0
Other Non Operating Income (Expenses)	0.47	0.47	1.05	0.32	0.63	-0.47
EBT Excluding Unusual Items	-2.14	-2.14	-2.83	-0.48	-1.11	-4
Other Unusual Items	0.05	0.05	0.03	0.01	0.15	-
Pretax Income	-2.09	-2.09	-2.8	-0.47	-0.96	-4
Net Income	-2.09	-2.09	-2.8	-0.47	-0.96	-4
Net Income to Common	-2.09	-2.09	-2.8	-0.47	-0.96	-4
Shares Outstanding (Basic)	156	156	119	108	72	34
Shares Outstanding (Diluted)	156	156	119	108	72	34
Shares Change (YoY)	31.35%	31.35%	10.05%	48.93%	110.34%	14.30%
EPS (Basic)	-0.01	-0.01	-0.02	-0.00	-0.01	-0.12
EPS (Diluted)	-0.01	-0.01	-0.02	-0.00	-0.01	-0.12
Free Cash Flow	-1.19	-1.19	-1.79	0.41	-0.99	-0.55
Free Cash Flow Per Share	-0.01	-0.01	-0.02	0.00	-0.01	-0.02
Gross Margin	-	-	-	100.00%	100.00%	-
Operating Margin	-	-	-	-45.71%	-186.72%	-
Profit Margin	-	-	-	-47.04%	-127.84%	-
Free Cash Flow Margin	-	-	-	41.35%	-131.57%	-
EBIT	-2.23	-2.23	-2.16	-0.46	-1.4	-3.45
EBIT Margin	-	-	-	-45.71%	-186.72%	-

Source: S&P Capital IQ. Standard template.